That's what I'm expecting after successful completion of the Kevetrin phase I trial. Many combo trials with other drugs that are paid for by other companies. The University of Bologna trial is likely the first of many.
In Reply to 'To infinity and beyond!'
What could ground the flight? Can try to think about bit about Kevetrin first. Of course there is the chance it does work so well, but let's say that it does. Cancer treatment is just on the cusp of revolutionary changes. This is not my opinion, it is that of lots of oncologists, such as a Dr Herbst head of Oncology at Yale whom I read quoted in an interview earlier today. He expects immunotherapy to change cancer treatment drastically in the next 5 years. Now you could argue that people are always saying that everything is about to change, but let's say he is right. I would like to be able to understand how K fits with CAR-T therapies. It is non-toxic, so it could be an additive to many regimens, and it seems as though it ought to provide extra anti tumor activity. Once CTIX Dana Farber figure out the best dosing I can imagine all sorts of people on the phone- or on LinkedIn- or however CEO's of pharma firms do business, calling/emailing Beverly and Dana Farber to line up a trial of Kevetrin.
This probably sounds overly optimistic- the airplane take off stuff-from me. But if Kevetrin will provide some benefit the lack of toxicity will be key to its use as an adjunct for lots of tumors.
News 
Market Data 
Discover 
AI
